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Abstract
The early days of the field of medical image computing (MIC) and computer-
assisted intervention (CAI), when publishing a strong self-contained method-
ological algorithm was enough to produce impact, are over. As a community,
we now have substantial responsibility to translate our scientific progresses
into improved patient care. In the field of computer-assisted interventions,
the emphasis is also shifting from the mere use of well-known established
imaging modalities and position trackers to the design and combination of
innovative sensing, elaborate computational models and fine-grained clini-
cal workflow analysis to create devices with unprecedented capabilities. The
barriers to translating such devices in the complex and understandably heav-
ily regulated surgical and interventional environment can seem daunting.
Whether we leave the translation task mostly to our industrial partners or
welcome, as researchers, an important share of it is up to us. We argue that
embracing the complexity of surgical and interventional sciences is manda-
tory to the evolution of the field. Being able to do so requires large-scale
infrastructure and a critical mass of expertise that very few research cen-
tres have. In this paper, we emphasise the need for a holistic approach
to computer-assisted interventions where clinical, scientific, engineering and
regulatory expertise are combined as a means of moving towards clinical im-
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pact. To ensure that the breadth of infrastructure and expertise required
for translational computer-assisted intervention research does not lead to a
situation where the field advances only thanks to a handful of exceptionally
large research centres, we also advocate that solutions need to be designed to
lower the barriers to entry. Inspired by fields such as particle physics and as-
tronomy, we claim that centralised very large innovation centres with state of
the art technology and health technology assessment capabilities backed by
core support staff and open interoperability standards need to be accessible
to the wider computer-assisted intervention research community.
Keywords: Computer-assisted intervention; valley of death; medical
devices; health technology assessment
1. The need for clinical impact in CAI research
Whether we like it or not, researchers, clinicians and funders are becoming
very much impact driven. In the healthcare domain, articulating societal
impact through a scientific and technology-focused research programme is
challenging. However, making research matter by, showing a strong focus
on a clinical area and, eventually demonstrating an improvement in patient
care, is much easier. As such, we believe that the future of computer-assisted
intervention (CAI) will be driven by the need for clinical impact. With this
in mind, it is important to rely on efficient means of translating research into
the clinic that also allow us to reach for scientific excellence.
1.1. The challenge of translation
The impact that CAI already had in clinical practice is undeniable. Surgi-
cal and interventional sciences (SIS) have historically been guided only by di-
rect vision and touch. SIS have been and still are undergoing a paradigm shift
as new technologies for data fusion, tool tracking, intra-operative imaging
and sensing are introduced. Image-guided intervention (IGI) and computer-
assisted intervention have already enabled greater surgical precision, result-
ing in reduced tissue trauma, co-morbidity and complications, in addition to
shortened procedures and hospital stays.
However, far too little CAI research has reached the clinic, despite initial
CAI systems appearing over 20 years ago. One major reason for this, is the
substantial infrastructure and breadth of expertise required to design, imple-
ment and validate complete clinical-grade systems. Currently, many scientific
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Figure 1: Illustration of the expertise required to translate computer-assisted intervention
research into clinical impact.
and technological developments are being pursued across a disparate group
of research laboratories highly specialised in a limited number of engineering
and clinical areas. The barriers to translation arising from the heavily reg-
ulated clinical environment, the cost of the required infrastructure and the
lack of open interfaces and interoperability standards among interventional
devices are enormous. We believe that having a very broad set of relevant
skills and know-how as illustrated in Fig. 1 (scientific expertise; clinical ex-
pertise; quality and regulatory affairs; good manufacturing practices; scal-
able engineering implementation; clinical trials; health economics; technology
transfer) in large unified centres open to the broad research community will
be key to go beyond these barriers and develop disruptive interventional sys-
tems that can be transferred to industry and become clinical standard of
care.
1.2. Broadening the scope of the research field
Optimal clinical outcomes by contemporary CAI systems are hindered
by predominant reliance on anatomical images, insufficient integration with
innovative sensing, actuation and therapeutic devices as well as challeng-
ing demands in terms of skilful equipment handling and data interpretation.
The potential to broaden the focus of CAI research and go beyond these
limitations is there though. Existing CAI systems make suboptimal use of
the large amount of data generated before and during interventions. Few, if
any, clinically available systems effectively combine pre- and intra-operative
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imaging and information despite computational tools having the potential
robustness and accuracy to carry out this task. Current surgical instruments
and intra-operative imaging and sensing devices do not fully exploit physio-
logic and pathologic tissue responses and only a very limited subset have been
integrated in CAI systems. There is also significant untapped potential to
optimise the surgical environment by increasing the consideration and man-
agement of interactions between the multiple devices and software solutions
present in the interventional suite.
It is our opinion that pathologically, anatomically and physiologically
optimal surgery can be achieved by combining diagnostic-quality imaging
and sensing with ergonomic smart instruments. Anatomical cues, which
have been driving interventional therapies for centuries, will eventually be
augmented by physiological and pathological insights.
2. Infrastructure to overcome the translation barriers
The paucity of translated CAI research can be explained by the existing
gap between where the research typically ends and the level of development
and validation that the industry requires to invest in the commercialisation
of an innovative technology with a bearable risk. Waiting for the industry
to fill the gap is certainly utopian. Furthermore, injecting more funding at
a project level is probably not the most efficient and cost-effective means of
crossing the proverbial MedTech’s “Valley of Death”.
Large-scale academic translational research platforms endowed with highly-
trained, multidisciplinary teams could underpin several projects and act as
a conduit to: demonstrate impact in clinical trials up to phase-III; improve
translational success rate; shorten bench-to-bedside time; increase technology
transfer through spin-off creation and licensing agreements.
To be succesful, these translational platforms need to embrace the com-
plexity of surgical and interventional sciences. The CAI community need to
go beyond animal experiments and push for strong Health Technology As-
sessment (HTA) programmes that focus on evaluating the clinical impact of
the developed technology. To this end, the translational platforms undoubt-
edly need to be associated with major teaching and research hospitals but
also need to create international networks where technology developed in one
centre can be clinically evaluated in another centre. System integration for
CAI hardware and software devices need to be designed with modularity and
interoperability in mind to ensure we capitalise on previous developments.
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Agile Quality Management Systems (QMS) need to be designed to take into
account the specific needs of the CAI researchers but ensure the safety of the
devices that are translated to the clinic and lower the barrier of technology
transfer.
2.1. Stronger Health Technology Assessment
Translational platforms will provide the required infrastructure to trans-
late clinically effective and affordable innovation to the bedside. They will
foster an ecosystem of projects focusing on key scientific, technological or
clinical questions. The platform will raise the quality of the research deliver-
ables to clinical standards which will allow for the evaluation of the clinical
relevance of a proposed device.
With sufficient trust in the development process of the devices in the
translational plateform, each plateform will be able to engage with other
international centres to set up multi-institutional HTA projects and assess
the clinical impact of the most promising innovative interventional systems.
Even with adequate resources, translating interventional devices into clin-
ical applications and evaluating their potential patient benefit is a complex
task given the regulations controlling introduction of novel devices into the
operating theatre or interventional suite. To streamline the HTA ambition
and initiate small and large clinical studies and trials, the platforms will need
to leverage strong system integration capabilities and rely on robust quality
management. This will enable the completion of robust clinical trials appli-
cations including compliant technical files and provide the necessary trust
among the network of translational plateforms.
By performing stronger clinical evaluation of disruptive CAI technology,
not only will we increase the clinical impact but also will we learn more
about what really matters to the clinicians and also will we make the tech-
nology much more attractive to potential commercial partners by making the
commercialisation risks much more supportable.
2.2. Modular System Integration
One of the key challenges of translating a medical device out of a re-
search lab into an interventional suite is that of integration within the in-
terventional workflow. Many research projects fail to reach this maturity,
especially for complex interventions requiring manipulation, dissection, and
navigation through soft, deformable tissue using a large variety of different
tools. This is because many research groups approach it from a scientific
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and technological perspective, solving a single piece of the puzzle, and do
not have a long-term strategic system integration plan.
From a platform perspective, several technological challenges that are of-
ten overlooked in CAI research actually manifest as clinical-translation road-
blocks. The common characteristics of these challenges revolve around (a)
lacklustre clinician experience stemming from inappropriate workflow inte-
gration, tool interaction, form factor and interface design, (b) inability to
implement research tools in theatres due to a lack of a common scalable
platform to interact with interventional clinical data sources and tools, (c)
stringent data security and management requirements, (d) lack of device-
design iterations and adherence to quality management standards through-
out the design lifecycle, (e) poor understanding of sterilisation and device
safety requirements. To successfully translate novel algorithms and devices
without incurring massive redevelopment costs, all these issues need to be
addressed in advance and in a holistic fashion.
Experienced system integration teams working within a quality manage-
ment framework is a cornerstone of the translational platforms we envision.
They will need to leverage Design Thinking approaches (Yock et al., 2015)
at an early stage in the development of the research to deliver lightweight
ergonomic user interfaces, robust and scalable modular systems supporting
both hardware and software innovations, secure patient data handling and
safe hardware components.
Interoperability standards need to be extended past imaging file format.
The DICOM Working Group 24 (WG24) has been established to develop
DICOM objects and services related to image-guided interventions (Treichel
et al., 2012) but interoperability questions need to receive more attention
from the CAI research community in order to move the field towards vendor-
neutral interfaces to control interventional devices. Common interfaces for
plug-and-play integration of a broad set of innovative devices that deliver
anatomical, physiological and pathological data or perform tissue manipula-
tion are needed. Interaction between scientists and hardware/software sys-
tem integration research engineers will allow for robust systems that operate
as intended, are user-proof, fail gracefully, and easily integrate in clinics.
2.3. Agile Quality Management
Medical devices are subject to increasingly stringent regulations to ensure
safety and clinical efficacy. The costs associated with developing a regulatory
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compliant product from prototypes developed without proper quality man-
agement (as common in the academic research setting) are often substantial.
Effective and efficient transfer between academic researchers and commercial
parties is frequently logistically difficult and time-consuming. Moreover, clin-
ical studies to provide high-quality supporting data on clinical efficacy are
also essential, but are typically highly resource-intensive, expensive, and rely
on partnerships with clinical research teams that SMEs, which constitute a
large proportion of the medical device sector, are usually unable to support.
All of these factors present substantial barriers to translating technologies
up to clinical adoption.
Our vision is that of a sustainable pipeline that enables early stage tech-
nology stemming from CAI research to be further developed into verifiably
safe medical devices that are ready for large-scale HTA and that can be
efficiently transferred to commercial parties. To realise this pipeline and
address the above issues, resources to support the development of medical
devices (including both hardware and software) in an agile QMS respectful of
both research needs and internationally recognised best development prac-
tice are needed. The primary benefits of implementing an agile QMS are
the ability to accelerate and reduce the risk of clinical translation by pro-
viding a formalised framework for medical technology development that is
much closer to that adopted in industry. This will also lead to a substantial
increase in the commercial value of CAI research. Finally, clinical evaluation
as part of a development process that is mindful of regulatory compliance
will strengthen the links between scientists, engineers and clinicians. An ag-
ile QMS will also support the implementation of robust clinical data systems
that enable tracking of real patient outcomes, which is key to clinical efficacy
assessment.
To be of further benefit, an agile QMS will need to work in close inter-
action with other regulatory compliant entities, including existing certified
QMSs in industry, to ensure that technology transfer to commercial parties
can indeed happen efficiently. The rationale is to significantly reduce the
need for, and burden of, re-engineering device/system prototypes developed
as part of academic research into a regulatory-compliant clinical prototype
or commercial product. This will also require the implementation of robust
processes for evaluating the technical merits and regulatory risks associated
with CAI research technology.
7
2.4. Creating large-scale open CAI research infrastructures
We have made the case that a critical mass of expertise and large-scale
infrastructures are needed to generate clinical impact from CAI research. One
of the pitfalls of implementing the translational platforms that can gather
the required breadth of infrastructure and expertise is to concentrate and
restrict CAI research to a handful of exceptionally large research centres.
The competitive advantage of a research team could therefore slide from
scientific excellence to shear group size and access to funding.
A few years ago, a situation not so dissimilar was at risk of happening in
the MIC community when access to clinical data and to privately held soft-
ware repository became a competitive advantage. The advent of 1) massive
open datasets such as coming from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) (Mueller et al., 2005), 2) grand challenges such as the Ret-
rospective Registration Evaluation Project (West et al., 1997), and 3) open
software toolkits such as ITK, VTK and 3D Slicer (Pieper et al., 2006), has
been transformative to the MIC field.
In the CAI domain, where real-time interaction with innovative hardware
devices is primordial, having access to similar retrospective datasets, valida-
tion challenges and open-source software such as IGSTK (Enquobahrie et al.,
2007), OpenIGTLink (Tokuda et al., 2009), PLUS (Lasso et al., 2014) and
NifTK (Clarkson et al., 2015) is a very important step but does not ade-
quately cover the hardware aspects and is not enough to offset the compet-
itive advantage provided by the massive infrastructure required for transla-
tional CAI research. In the specific subfield of medical robotics, the RAVEN-
II platform (Hannaford et al., 2013) provides an appreciated step forward but
does not address the question of infrastructure needs. To provide realistic
environments for designing and evaluating CAI systems, we believe it is es-
sential to have dedicated-for-research mock operating theaters and interven-
tional suites endowed with as open as possible, state-of-the-art equipement:
CT scanner, interventional MRI, rotational X-ray 3D imaging system, ul-
trasound system, surgical robots, classical therapeutic instruments, thera-
peutic lasers, optical and EM tracking systems, surgical endoscopes, surgical
neuro- and ophthalmic- microscopes, realistic phantoms, surgical lights, op-
erating table, insuﬄators, etc. Achieving this goal requires going beyond
what the current most advanced surgical innovations centres such as the US
P41-funded National Center for Image Guided Therapy (NCIGT) and its
flagship Advanced Multimodality Image Guided Operating (AMIGO) facil-
ities (Jolesz, 2014) or the IRCAD facilities (Marescaux and Diana, 2015)
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provide. We need a stronger focus on translating hardware and software de-
velopments, and wide collaboration networks with joint international funding
mechanisms.
While the scale of the infrastructure required does not quite approach that
in very infrastructure-heavy fields such as particle physics and astronomy,
lessons can be learned from how these fields mitigate the risk of the research
being concentrated in a handful of research teams.
CERN, the European Organization for Nuclear Research, operates the
largest particle physics laboratory in the world. It employs just under 2,400
people, knowing that there are 10 times more engineers and technicians em-
ployed by CERN than research physicists. What provides the bulk of CERN
research output are its 10,000 visiting scientists from over 600 universities
over the world. The CAI translational platforms will similarly need to fos-
ter international collaborations. Visiting scientists should be provided with
full access to the platform infrastructure and expertise during their visit and
should be allowed to rely on the data acquired during their visit to pursue
their research. Appropriate contractual agreements will of course be required
to cover the confidentiality, and intelectual property (IP) requirements.
Trade-offs between IP protection to increase technology transfer and re-
search openness to increase scientific impact will need to be designed. It is
interesting to also look at the European Southern Observatory (ESO), an or-
ganisation that focuses on the design, construction and operation of powerful
ground-based observing facilities for astronomy. Technology transfer at ESO
has for example opened the market for active and adaptive optics which is
now gaining traction in the biomedical imaging field. Data from ESO results
in over two peer-reviewed publications per day. Visiting astronomers have
exclusive access to their scientific data for about a year after which the data
is made publicly available for further research.
In the CAI translational platforms, creating holistic communities that
spans clinicians, engineers, regulatory specialists, and entrepreneurs in resi-
dence and allowing individuals to work side-by-side and interact freely within
these interdisciplinary environments will be key success enabler.
3. A biased view on emerging research themes
Having pledged that large-scale open translational research infrastruc-
tures will allow the CAI research field to move towards stronger clinical
impact, it is now interesting to consider what the emerging research topics
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are that will keep the field active and thriving in the years to come. Far
from aiming for exhaustivity, we will provide a biased, personal view on this
question.
It is clear that the surgeon’s workspace and assessment of the surgical
site are severely limited in image-guided intervention and minimally invasive
surgery. This increases the importance of detailed surgical planning and
surgical navigation and calls for improved pre- and intra-operative imaging
and sensing as well as ergonomic actuation and tissue manipulation.
We envision three important overlapping directions in which the CAI
research will move to address these challenges in the future. Physiological
navigation will replace the current, mostly anatomical, navigation. Clinical
team experience considerations will move the field beyond the analysis of
established workflow of the surgeon towards proposing optimised workflows
in terms of cognitive and ergonomic workload for the complete clinical team.
Precision instrumentation research will focus on designing devices that both
sense physiological/pathological information and interact with tissue to de-
liver therapy.
3.1. Physiological navigation
Almost all current surgical navigation systems rely on rigid, static 3D
representations of human anatomy with pathology being manually delineated
from conventional diagnostic imagery. Navigation has had a major impact in
orthopaedics and neurosurgery. This is illustrated in Fig. 2 where fusion of
pre- and intra-operative imaging is used to improve resection in the context
of epilepsy surgery (Duncan et al., 2016). The potential elsewhere is however
still to be realised. We suggest a paradigm shift will happen in which the
full range of physiological information from a wide range of sensors is used in
conjunction with data-driven learning and computational modelling to: (1)
better assess the current status of the tissue being manipulated; (2) better
predict tissue motion; (3) better assess impact of the intervention on normal
tissue; and, (4) better predict the outcome of the therapeutic or interven-
tional process.
First, novel imaging, sensing and data fusion techniques will be sought to
generate much more accurate ways to precisely assess the state and extent
of any abnormality as well as identify and locate structures at risk, thereby
enabling better prognosis for disease spreading and its effect on function. In
cancer, this might take the form of novel molecular-based precision-targeted
therapy for pre-malignant disease that requires removal to reduce the risk of
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Figure 2: Pre- and post-operative recording of resection. A) Intra-operative photograph
of left frontal region. B) Modelling of gyral and vascular anatomy. C) Intra-operative pho-
tograph of left frontal resection. D) Reconstruction of completed resection. E,F) Coronal
and sagittal intra-operative MRI showing completed resection, incorporating neurophysi-
ological landmarks of ictal onset (red) and propagation to anterior cingulum and medial
orbito-frontal area (orange). Image courtesy of Mark Nowell.
future malignant transformation. In orthopaedics this might involve better
prediction of the cascade of events that lead to severe arthritic damage to
the knee, hip or shoulder joints. By fusing and integrating novel technologies
in the interventional workflow, detection and prediction both pre-operatively
and intra-operatively will be inproved.
Second, learnt motion models to better predict the motion and tissue dis-
tortions associated with autonomous motion (e.g. breathing, cardiac motion,
gut peristalsis, bladder filling etc.), or with patient positioning and weight
loss or gain that might take place between pre-operative imaging and therapy
will be proposed (Johnsen et al., 2015).
Third, physiological modelling will better predict iatrogenic harm, i.e.
caused by the intervention itself. All ablative procedures and all surgery
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result in iatrogenic damage to adjacent tissues or tissues that prevent access.
The balance between complete treatment but excessive harm on one side and
inadequate but “safe” treatment on the other is currently made subjectively
by the clinician. It is likely that this balance is far from optimal in many
situations. The likelihood of a particular procedure harming the surrounding
normal tissues varies significantly between tissue types and patients. For
example, in prostate cancer, harm to normal prostate tissue has relatively low
impact while harm to the adjacent vascular bundles, rectal wall or urethra
can have a profound effect. In neurosurgery, some parts of the brain are
remarkably resilient to damage while other eloquent areas (e.g. speech or
movement areas) are extremely sensitive to damage. The boundaries between
the two are tight and often difficult to determine. Appropriate models will
improve surgical planning and guidance (Hayashi et al., 2015). Such systems
could also help explain surgical or interventional risks to patients as part of
the informed consent.
Fourth, physiological modelling will better predict the interventional pro-
cesses. For surgery, this involves modelling tissue resection, tissue-remodelling
and inflammation. For radio-frequency / high-intensity focused ultrasound /
micro-wave ablative processes, this entails modelling the physical processes of
heat transport; etc. Whenever possible, computational models will be driven
by real-time monitoring to extrapolate and improve the assessment of the
therapy. Coupling affordable sensing technologies with accurate modelling
based on patient-specific data will be an area of significant interest and rapid
development.
There is a crucial balance between learnt models from observation and
models informed by an understanding of physiological and patho-physiological
processes. This balance will evolve over time to produce accurate predictive
assessment of interventional outcome coupled with multi-modal sensory guid-
ance.
3.2. Clinical team experience
The performance and capabilities of the surgical team need to be en-
hanced not only by facilitating better training, but also through end-to-end
ergonomic design and effective online information management to improve
the clinical experience, identify real-time workflow-related risks and inform
the team about how to ensure optimal patient safety.
Modern therapeutic environments, from operating theatres to endoscopy
suites, are increasingly complex, with poorly integrated intra-operative de-
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vices, sensors and support infrastructures. Furthermore, existing surgical /
interventional training systems only offer over-simplified representations of
basic generic skills that are not specifically adapted to the patient undergo-
ing therapy. This leads to long learning curves, imposes a heavy cognitive
and ergonomic workload on the clinical team, and slows the uptake of novel
interventional tools. As a consequence of suboptimal design, limited train-
ing, understanding and support, new technologies are often introduced in
theatre but are then left under-utilised. To tackle this problem, advanced
training centres are emerging for specialist surgical skills training. Yet, the
opportunity to use these training centres for quantitative skills and clini-
cal workload assessment and for driving the research towards an improved
clinical experience has not yet been fully realised.
A first research focus will rely on developing the sensory and computa-
tional tools to understand, measure, and evaluate operator behaviour within
the interventional setting. Skill and workflow analysis are the most ma-
ture components of clinical behaviour analysis, with techniques developed to
provide patient- and surgery-specific training systems. This will be develop
further by combining multi-sensory data over multiple scales, from entire
theatre track spaces (providing information about user interactions) down
to vision-based instrument end effector localisation and tissue tracking. The
context at the various scales that the interventional environment workflows
require will be leveraged to introduce a step change to previous skills and
workflow analysis methodologies that have mostly been relying on motion
tracking and analysis. Crucially, these workflows will involve the full clinical
team and not only the trainee or expert surgeon.
A second research focus will rely on context-awareness to improve user
experience of the clinical team and inform clinical decision support systems,
thus paving the way to introducing some automation in theatre. Indeed, de-
spite recent efforts and the introduction of integrated interventional suites,
there is little coordinated effort to optimise theatre and interventional suite
ergonomics, workflow and operation in routine practice. Theatre staff lack
the analytical tools and information to help them plan and refine the er-
gonomics and use of equipment during surgery, as well as tools that provide
real-time decision support and coordination during an intervention. CAI re-
search will develop the interfaces and effective information delivery systems
to help staff optimise the use of surgical equipment, theatre and interven-
tional suite ergonomics, and to provide critical safety information, such as
radiation levels in different parts of the catheter lab or endoscopy suite. Task-
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driven information compression providing the right information at the right
time will be designed to reduce intra-operative cognitive workload. Workflow
analysis and automation will allow for ergonomic, procedure-specific integra-
tion of surgical devices in the complex, safety-critical environment of the
therapeutic suite. Research in assistive technology will provide solutions to
compensate for the reduced workspace and dexterity in minimally-invasive
therapy.
3.3. Precision instrumentation
The interventional suite of the future will not only optimise the clinical
team ergonomic and cognitive load by streamlining the interventional work-
flow, but will also feature a shift from external imaging systems with passive
interventional devices to smart miniature devices that allow the interven-
tionist to understand local tissue properties through integrated imaging and
sensing, and deliver optimal local therapy accordingly. CAI research will de-
velop tracked interventional tools that allow for imaging with molecular and
microstructural contrast, providing dexterity for flexible physiological access
and for therapy at the micron-scale level.
Molecular and microstructural visualisation of tissue will be delivered by
a combination of modalities such as endoscopic multi-spectral photoacoustic
(Beard, 2011), all-optical pulse-echo ultrasound imaging (Colchester et al.,
2014), targeted fluorescence imaging and different forms of endomicroscopy
(Thiberville et al., 2007). By tailoring the imaging to the application, dif-
ferentiation between tissue types will be achieved, thus directly coupling the
output of precision instruments to the research in physiological navigation.
Molecular image contrast will be valuable in a wide range of percutaneous
procedures such as peripheral nerve blocks, for identifying critical structures
including vessels and nerves that are invisible in X-ray fluoroscopy, and be-
yond the field of view of external ultrasound (Mari et al., 2015).
Spatial tracking of medical devices will be crucial to interpret the ac-
quired high-resolution images of tissue in the macroscopic intervention-level
context. Novel tracking means such as coded ultrasonic tracking, in which
ultrasound transmissions from external imaging probes are received by sen-
sors integrated within the medical devices, and Fibre-Bragg gratings will
determine the location and orientation of devices with greater accuracy and
integration flexibility. These technologies will enable multi-scale fusion of
pre-operative and intra-operative anatomical images with the molecular-level
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information provided by other instruments. With spatial tracking, cartogra-
phies of pathological locations can be created. Image and data compounding
will provide high-resolution volumetric images of large field-of-views to sup-
port physiological navigation.
Precise actuation at microscopic and macroscopic scales will be achieved
using micro-manufactured super-elastic components, electroactive polymers,
and pneumatically actuated microtubes in combination with shape sensing
using patterned carbon nanotube - PDMS composite polymer skins, and
Fibre-Bragg gratings. These actuator technologies will form the backbone of
steerable surgical tools, which will allow access to hard-to-reach or currently-
impossible-to-reach anatomical regions, such as accessing the brain and optic
nerve by flexing around the ocular cavity, safely reaching the deepest regions
of the human cochlea, or navigating the spinal canal to individually address
damaged nerve roots, vascular malformations and disc herniations (Bergeles
et al., 2015).
Multimodal sensing technologies will be developed using sub-micrometre
3D printing as well as soft and flexible photolithography to integrate ar-
rays of flexible and minimally-invasive sensors directly on the interventional
tool (Schneider et al., 2015). Equipped with flexible patterned surfaces for
e.g. force, pressure, and temperature sensing, microscale interactions with
the manipulated tissue will be recorded. This sensory information will en-
able tissue property mapping at high spatial resolution for precise surgical
guidance and smart co-manipulation of the instruments, allowing the inter-
ventionist to focus on executing the macroscopic level of complex surgical
plans. These new precision instruments will thus blend into existing work-
flows, and this minimal disruption of clinical protocols will facilitate their
clinical translation.
The advances in local imaging, tracking, and actuation will be brought
together to facilitate the delivery of novel therapies to specific tissue targets,
minimising collateral damage. Novel instruments will enable pressure-safe de-
livery of microvolumes of stem cells, genes, and drugs for localised treatments.
In ophthalmology, for example, force-perceptive ultra-precise instrument for
accessing and delivering sight-restoring stem cells into the subretinal lay-
ers could providing a cure to Age-Related Macular Degeneration blindness
(Carr et al., 2013). Further, high-intensity focused ultrasound (HIFU) ef-
fected and monitored using optical carbon-nanotube-PDMS-composite-based
ultrasound transmitters embedded into interventional instruments will allow
for precise tumour ablation and traversal of vascular occlusions to treat hard
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to reach pathological regions.
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Figure 3: Example building blocks of a holistic approach to computer-assisted intervention
in the context of epilepsy surgery (top row) and fetal surgery (bottom row) (Pratt et al.,
2015).
4. Conclusion
In the year to come, the success of computer-assisted intervention research
will be evaluated by the clinical impact resulting from its scientific results.
Given the important infrastructure and expertise required to make CAI re-
search clinically usable and relevant to the clinical teams, the temptation to
leave the translation step to the industry is strong but not efficient.
We have argued that large-scale open translational CAI research infras-
tructures need to be created and need to foster international collaborations
beyond algorithms and software. A holistic approach embracing the com-
plexity of surgical and interventional sciences needs to be taken throughout
all the clinical steps, illustrated in Fig. 3, from the consolidation of prior
knowledge, to the design and exploitation of smart instrumentation and to
long-term outcome analysis.
The interventional systems resulting from the upcoming CAI research will
not only make existing interventions easier, safer, and more precise, but will
become enablers for new and currently impossible surgical applications.
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